SEC Filing Summary
Business Context and Reporting Period
This Form 8-K was filed by Anzu Special Acquisition Corp I on March 28, 2023, with the report signed April 3, 2023. The filing concerns the unaudited interim financial statements for the quarter and nine months ended September 30, 2022. The provided metadata identifies Envoy Medical, Inc., but the filing’s registrant is Anzu Special Acquisition Corp I.
Financial Metrics and Liquidity
- The filing does not provide revised revenue, profit, margin, cash flow, debt, or liquidity amounts.
- The Company stated that the accounting correction is not expected to affect its cash position or cash held in the trust account established in connection with its initial public offering.
- The correction affects the classification of an extinguishment of a contingent liability and the related statements of operations, changes in stockholders’ deficit, and cash flows for the affected period.
Material Changes Versus the Prior Comparable Period
Previously issued unaudited interim financial statements in the September 30, 2022 Form 10-Q should no longer be relied upon. The Company will restate the affected financial statements in its Form 10-K for the year ended December 31, 2022.
The issue arose from a deferred underwriters’ commission recorded as a contingent liability at the March 2021 IPO closing. After an underwriter waived all claims to the commission in September 2022, the Company recorded a non-operating gain. Management later concluded that the extinguishment should have been recorded as a credit to stockholders’ deficit rather than in the statement of operations.
Guidance, Risks, Contingencies, and Unusual Items
- Management concluded that a material weakness existed in internal control over financial reporting and that disclosure controls and procedures were ineffective as of December 31, 2022.
- Management and the Audit Committee discussed the matter with WithumSmith+Brown, PC, the independent registered accounting firm.
- The filing includes customary forward-looking statements regarding cash and trust-account balances, subject to risks and uncertainties. The Company undertook no obligation to update them.
Investor Verification Priorities
- Verify the restated September 30, 2022 financial statements in the subsequent Form 10-K.
- Confirm the final accounting treatment and dollar impact of the waived deferred underwriting commission.
- Assess remediation of the identified material weakness and any effect on disclosure controls.
- Confirm that cash and trust-account balances were unchanged after the restatement.